drugset / Trial / NCT00040313

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

NCT00040313

Phase 2 Completed Eyetech Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether pegaptanib sodium (Macugen) is safe and effective in slowing the leakage of fluid within the retina and thereby stabilizing or improving vision when compared to placebo injections. A total of 176 patients will be enrolled

Timeline

Start
2002-10
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer Intravitreal